Critically, the proportion of CD161+ BCMA CAR‐T cells in MM was substantially larger than that of PD‐1+ BCMA CAR‐T cells, with the difference becoming even more pronounced at later stages (>30 days) (Figure 6D). This evidence concerns the gene KLRB1 and Miyoshi myopathy.